SGX Market Updates

The Straits Times Index (STI) Led Asia Pacific & Developed Stock Benchmarks in 2022


PUBLISHED ON |

09 January 2023

  • In 2022, the STI generated a 4.1% price gain, with dividend distributions boosting the total return to 8.4%. This was the strongest stock benchmark performance for year 2022 across the Asia Pacific and Developed Indices, with the FTSE Asia Pacific Index and FTSE Developed Indices declining 16.7% and 18.3% in total return respectively.

  • Index performances were attributed to multiple factors including sector composition and secular growth, in addition to broader regional and global economic themes. Multiple STI constituents also pressed on with strategic initiatives in 2022. Overarching themes for 2023 include slowing global growth and trade, and persistent above-trend inflation.

  • For Singapore-listed ETFs, the STI remained the most traded index among ETF investors, with the 2 STI tracking ETFs recording a combined trading turnover of S$1.06 billion in 2022. Primary market unit creations and redemptions crossed S$553 million over the period.




The Straits Times Index (STI) generated a 4.1% price gain in 2022, with reinvested dividends bringing the total return to 8.4%. For much of the year, the STI was among the strongest stock market benchmarks across the globe, and for the majors finished the calendar year just 1.0% behind Brazil’s IBOVESPA Index. This means the STI well outpaced Indices across the Asia Pacific and Developed Economies across the globe over the year.



Performance of STI vs Asia Pacific & Developed Stock Benchmarks in 2022



The STI’s gain in 2022 brought the STI’s gain from the end of 2019 through to the 9 Jan 2023 Morning Session to 14.0%, outpacing a comparatively flat performing region, while marginally trailing the FTSE Developed Index total return of 18.0%.

Last year, the STI remained the most traded stock index among Singapore ETF investors, with the two STI tracking ETFs recording a combined trading turnover of S$1.06 billion in 2022. This was 25% higher than the next most traded index, the Hang Seng TECH Index which traded S$850 million over 2022. Primary market unit creations and redemptions for the 2 STI ETFs, crossed S$553 million over the period with fluid economic developments producing a close to 500-point range for the STI in 2022, up from near 440 points in 2021.



Index Drivers

For the 2022 year, the trio of DBS (SGX:D05), OCBC (SGX:O39) and UOB (SGX:U11) ended 2022 with a 46.9% weight in the STI. The trio averaged 13% total returns over the year. On the back of higher interest rates, the trio of banks have reported 8 consecutive quarters of q-o-q NII growth, with the combined 3Q22 NII at S$7.4 billion, up S$1.3 billion from 2Q22.

By comparison, the Bank Sector makes up 6.3% of the FTSE Developed Index and 7.3% of the FTSE All-World Index, which maintain the most Sector exposure to Technology, which was the least performing sector of 2022.

Aside from secular sector performances, growth outlooks also impacted index performances. For instance, while maintaining a 20% exposure to the Bank Sector and a 2% exposure to the Technology Sector, downward growth revisions for Asia’s largest economy saw the FTSE China A50 Index decline 22% in 2022. With risk management applications, the SGX FTSE China A50 Index Futures market generated record average daily trading turnover in 2022 for both the day and overnight sessions.

The USD/CNY also appreciated 15% over the first 10 months of 2022. The comparative strength of the Singapore Dollar to the US Dollar was also a contributing factor to the STI’s performance. The FTSE ASEAN All-Share Index which declined 6.8% in 2022 maintains a 31% weighting to Bank Sector, including an 11% combined weightage to DBS (SGX:D05), OCBC (SGX:O39) and UOB (SGX:U11). While pressing higher for most of the year, the USD/SGD ended the year marginally lower at 1.34, whilst 3 countries that represent close to 60% of the FTSE ASEAN All-Share Index booked depreciations to the USD. The USD/THB ended the year up 4%, the USD/IDR ended the year up 9% and the USD/MYR ended the year up 6%.

In addition, since 2020, multiple corporates have engaged strategic initiatives to enhance operational efficiency and shareholder value. Such initiatives have involved acquisitions, disposals, significant share buybacks, restructuring or pivots to new revenue streams. This theme was also relevant to 8 of the 10 strongest performing STI stocks that were listed for the full 2022 year.



STI Stocks
(Sort by Turnover in 2022)
SGX
Code
2021
Total
Return
%
2021 Net
Institutional
Fund Flow
S$M
2022
Price
Change
%
2022
Total
Return
%
2022 Net
Institutional
Fund Flow
S$M
Sector
DBS D05 35 1,172 4 8 -297 Financial Services
UOB U11 24 451 14 19 -72 Financial Services
OCBC O39 17 125 7 12 474 Financial Services
SingTel Z74 3 -303 11 16 842 Telecommunications
CapitaLand Integrated Commercial Trust C38U 0 -89 0 3 87 REITs
Yangzijiang Shipbuilding BS6 45 206 95 107 39 Industrials
CapitaLand Ascendas REIT A17U 2 -251 -7 -2 -139 REITs
CapitaLand Investment *** 9CI 16 56 9 13 106 Financial Services
Wilmar International F34 -7 -261 1 5 85 Consumer Non-Cyclicals
Mapletree Pan Asia Commercial Trust * N2IU -2 -54 -17 -12 -170 REITs
Keppel Corporation BN4 -1 -121 42 49 357 Industrials
SIA C6L 17 -558 11 13 123 Industrials
Jardine Matheson J36 3 -75 -8 -4 -12 Industrials
Mapletree Logistics Trust M44U -1 -86 -16 -12 -104 REITs
SGX S68 4 -286 -4 0 -13 Financial Services
ST Engineering S63 2 -112 -11 -6 -142 Industrials
Genting Singapore G13 -8 -104 23 26 258 Consumer Cyclicals
Hongkong Land H78 35 -10 -12 -8 24 Real Estate (excl. REITs)
Mapletree Industrial Trust ME8U -1 -177 -18 -13 -198 REITs
Venture Corporation V03 -2 -155 -7 -3 -70 Technology
Jardine Cycle & Carriage C07 9 38 39 45 203 Consumer Cyclicals
City Developments C09 -13 -306 24 27 310 Real Estate (excl. REITs)
Thai Beverage Y92 -8 -363 4 7 -26 Consumer Non-Cyclicals
Sembcorp Industries U96 20 89 69 73 219 Utilities
SATS S58 -2 -28 -27 -27 -140 Industrials
Frasers Logistics & Commercial Trust BUOU 14 4 -24 -19 -49 REITs
Keppel DC REIT AJBU -8 -206 -28 -25 -155 REITs
UOL Group U14 -6 -30 -5 -3 -9 Real Estate (excl. REITs)
DFI Retail Group D01 -28 -74 2 5 -3 Consumer Non-Cyclicals
Emperador ** EMI N/A N/A 13 13 -5 Consumer Non-Cyclicals

* does not include net institutional flow for Mapletree North Asia Commercial Trust (MNACT).
** price and total return from 14 July 2022.
*** 2021 total return from 20 September 2021.
Source: SGX, Refinitiv, Bloomberg.



Growth, trade, and inflation are the overarching macro themes for 2023, with the global stock and bond markets pricing in moderate recessionary pressures in 2023. Broad downside risks to the market in 2023 are twofold. Firstly, added global interest rate increases may further decelerate growth or exacerbate market volatility and financial stability risks. Secondly, there may be further escalation in global geopolitical tension.







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












SGX Stock / REIT Search

Advertisement

Trust Bank God Of Fortune Referral Code PGKPSWAE Trust Bank Referral Code 🧧

Advertisement